441 related articles for article (PubMed ID: 31154940)
1. Afirma Gene Sequencing Classifier Compared with Gene Expression Classifier in Indeterminate Thyroid Nodules.
Endo M; Nabhan F; Porter K; Roll K; Shirley LA; Azaryan I; Tonkovich D; Perlick J; Ryan LE; Khawaja R; Meng S; Phay JE; Ringel MD; Sipos JA
Thyroid; 2019 Aug; 29(8):1115-1124. PubMed ID: 31154940
[No Abstract] [Full Text] [Related]
2. Performance of Afirma genomic sequencing classifier vs gene expression classifier in Bethesda category III thyroid nodules: An institutional experience.
Zhang L; Smola B; Lew M; Pang J; Cantley R; Pantanowitz L; Heider A; Jing X
Diagn Cytopathol; 2021 Aug; 49(8):921-927. PubMed ID: 34021740
[TBL] [Abstract][Full Text] [Related]
3. Real-world Comparison of Afirma GEC and GSC for the Assessment of Cytologically Indeterminate Thyroid Nodules.
San Martin VT; Lawrence L; Bena J; Madhun NZ; Berber E; Elsheikh TM; Nasr CE
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31665322
[TBL] [Abstract][Full Text] [Related]
4. Independent Comparison of the Afirma Genomic Sequencing Classifier and Gene Expression Classifier for Cytologically Indeterminate Thyroid Nodules.
Angell TE; Heller HT; Cibas ES; Barletta JA; Kim MI; Krane JF; Marqusee E
Thyroid; 2019 May; 29(5):650-656. PubMed ID: 30803388
[No Abstract] [Full Text] [Related]
5. Performance of Afirma Gene Sequencing Classifier versus Gene Expression Classifier in thyroid nodules with indeterminate cytology.
Yang Z; Zhang T; Layfield L; Esebua M
J Am Soc Cytopathol; 2022; 11(2):74-78. PubMed ID: 34366280
[TBL] [Abstract][Full Text] [Related]
6. Performance of the Afirma genomic sequencing classifier versus gene expression classifier: An institutional experience.
Wei S; Veloski C; Sharda P; Ehya H
Cancer Cytopathol; 2019 Nov; 127(11):720-724. PubMed ID: 31536167
[TBL] [Abstract][Full Text] [Related]
7. Single Institution Experience with Afirma and Thyroseq Testing in Indeterminate Thyroid Nodules.
Gortakowski M; Feghali K; Osakwe I
Thyroid; 2021 Sep; 31(9):1376-1382. PubMed ID: 33764195
[No Abstract] [Full Text] [Related]
8. Molecular testing for indeterminate thyroid nodules: Performance of the Afirma gene expression classifier and ThyroSeq panel.
Jug RC; Datto MB; Jiang XS
Cancer Cytopathol; 2018 Jul; 126(7):471-480. PubMed ID: 29637728
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Afirma Gene Expression Classifier with Gene Sequencing Classifier in indeterminate thyroid nodules: A single-institutional experience.
Geng Y; Aguilar-Jakthong JS; Moatamed NA
Cytopathology; 2021 Mar; 32(2):187-191. PubMed ID: 33010060
[TBL] [Abstract][Full Text] [Related]
10. Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes.
Baca SC; Wong KS; Strickland KC; Heller HT; Kim MI; Barletta JA; Cibas ES; Krane JF; Marqusee E; Angell TE
Cancer Cytopathol; 2017 May; 125(5):313-322. PubMed ID: 28152275
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of cancer and the benign call rate of afirma gene classifier in
Endo M; Sipos JA; Ringel MD; Porter K; Nagaraja HN; Phay JE; Shirley LA; Long C; Wright CL; Roll K; Nabhan FA
Cancer Med; 2021 Feb; 10(3):1084-1090. PubMed ID: 33449450
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic performances of the Afirma Gene Sequencing Classifier in comparison with the Gene Expression Classifier: A meta-analysis.
Vuong HG; Nguyen TPX; Hassell LA; Jung CK
Cancer Cytopathol; 2021 Mar; 129(3):182-189. PubMed ID: 32726885
[TBL] [Abstract][Full Text] [Related]
13. An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules.
McIver B; Castro MR; Morris JC; Bernet V; Smallridge R; Henry M; Kosok L; Reddi H
J Clin Endocrinol Metab; 2014 Nov; 99(11):4069-77. PubMed ID: 24780044
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Afirma GEC and GSC to Nodules Without Molecular Testing in Cytologically Indeterminate Thyroid Nodules.
Polavarapu P; Fingeret A; Yuil-Valdes A; Olson D; Patel A; Shivaswamy V; Matthias TD; Goldner W
J Endocr Soc; 2021 Nov; 5(11):bvab148. PubMed ID: 34708178
[TBL] [Abstract][Full Text] [Related]
15. Clinical Factors Influencing the Performance of Gene Expression Classifier Testing in Indeterminate Thyroid Nodules.
Wu JX; Young S; Hung ML; Li N; Yang SE; Cheung DS; Yeh MW; Livhits MJ
Thyroid; 2016 Jul; 26(7):916-22. PubMed ID: 27161519
[TBL] [Abstract][Full Text] [Related]
16. The impact of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on the performance of the Afirma gene expression classifier.
Hang JF; Westra WH; Cooper DS; Ali SZ
Cancer Cytopathol; 2017 Sep; 125(9):683-691. PubMed ID: 28544601
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive Follicular Variant of Papillary Thyroid Carcinoma and the Afirma Gene-Expression Classifier.
Wong KS; Angell TE; Strickland KC; Alexander EK; Cibas ES; Krane JF; Barletta JA
Thyroid; 2016 Jul; 26(7):911-5. PubMed ID: 27219469
[TBL] [Abstract][Full Text] [Related]
18. Repeat Fine Needle Aspiration Cytology Refines the Selection of Thyroid Nodules for Afirma Gene Expression Classifier Testing.
Nishino M; Mateo R; Kilim H; Feldman A; Elliott A; Shen C; Hasselgren PO; Wang H; Hartzband P; Hennessey JV
Thyroid; 2021 Aug; 31(8):1253-1263. PubMed ID: 33813868
[No Abstract] [Full Text] [Related]
19. How "suspicious" is that nodule? Review of "suspicious" Afirma gene expression classifier in high risk thyroid nodules.
Roychoudhury S; Klein M; Souza F; Gimenez C; Laser A; Shaheen Cocker R; Chau K; Das K
Diagn Cytopathol; 2017 Apr; 45(4):308-311. PubMed ID: 28188700
[TBL] [Abstract][Full Text] [Related]
20. American Thyroid Association Sonographic Risk and Afirma Gene Expression Classifier Alone and in Combination for the Diagnosis of Thyroid Nodules with Bethesda Category III Cytology.
Arosemena M; Thekkumkattil A; Valderrama ML; Kuker R; Castillo RP; Sidani C; Gonzalez ML; Casula S; Kargi AY
Thyroid; 2020 Nov; 30(11):1613-1619. PubMed ID: 32364010
[No Abstract] [Full Text] [Related]
[Next] [New Search]